You are now leaving an Amgen-owned website.
Amgen does not endorse or accept liability for websites controlled by third parties

Go back Continue

GBR-NP-0624-80003 | August 2024

OTEZLA®:
A simple choice for your patients with Psoriasis or Psoriatic Arthritis

otezla-icon1Long-term efficacy and safety profile in psoriasis and PsA1,2
otezla-icon2Flexibility of remote initiation and supply options
otezla-icon3No tuberculosis, viral hepatitis and liver function laboratory pre-screening required1
otezla-icon4Oral administration, with an intracellular mode of action1
otezla-icon5No ongoing, routine drug-specific laboratory monitoring required1

OTEZLA® is indicated for patients with Psoriasis or Psoriatic Arthritis

Psoriasis-women mob Psoriasis-women

Psoriasis

A Psoriasis patient who could benefit from Otezla® will present with:

  • Less severe psoriasis (PASI 10-15)3
  • High-impact areas (nail, scalp, palmoplantar) and symptoms3,4
  • They need a step up from a conventional systemic3
  • They experience a high burden on their quality of life and social impact3

Efficacy in psoriasis

*Otezla® is contraindicated in pregnancy. Pregnancy should be excluded before treatment can be initiated. Women of childbearing potential should use an effective method of contraception during treatment. Otezla® should not be used during breast feeding.

Psoriatic Arthritis manPsoriatic Arthritis man mob

Psoriatic Arthritis

A PsA patient who could benefit from OTEZLA® will present with:

  • Moderate PsA (3–7 tender and swollen joints involved)
  • High-impact domains (enthesitis, dactylitis) and symptoms5
  • Needs a step up from a conventional DMARD
  • Daily life:
    • Busy work
    • Demanding family life
    • Travels frequently to regular appointments and monitoring

DMARD, disease-modifying anti-rheumatic drug; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis.

  • References
    1. OTEZLA® Summary of Product Characteristics:
    2. Kavanaugh A, et al. Arthritis Res Ther. 2019;21:118
    3. Augustin M. et al. J Eur Acad Dermatol Venereol. 2021;35:123-134
    4. Rich P, et al. J Am Acad Dermatol. 2016:74:134-142:
    5. Bagel J, Schwartzman S. Am J Clin Dermatol, 2018:19(6):839-852
GBR-407-1224-80008 | February 2025
  • Adverse Event Reporting Information
    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Amgen Limited on +44 (0) 1223 436441.
privacy_tip
This is a promotional site intended for healthcare professionals in the UK. Not a healthcare professional? Click here